Patent application enters PCT phase, SpectraCure ensures development and work

SpectraCure’s work and development proceeds with several parallel projects. A…


Agreement signed with Memorial Sloan Kettering Cancer Center in New York

SpectraCure AB (publ) and Memorial Sloan Kettering Cancer Center in New York,…


Focus on technology and system development, and on the conduct of clinical trials

Fourth quarter (1 October – 31 December 2019) Other income amounted to TSEK 1…


Reinforcements in SpectraCure's organization

Today we are welcoming Johan Glindre to SpectraCure. Johan Glindre will be…


Exercise rate of 98.8 percent for SpectraCure’s warrants (TO3)

On 29 November, SpectraCure AB (publ) (“SpectraCure”) ended the exercise period…


SpectraCure´s main owner subscribes in full for his share

SpectraCure’s main owner and CEO Masoud Khayyami subscribes in full through his…


SpectraCure AB. Quarterly Report (1 July to 30 September) 2019

Third quarter (1 July – 30 September 2019) SpectraCure AB Quarterly Report The…


The FDA's initiative can provide faster market access for SpectraCure

During SpectraCure's ongoing clinical trial, the American FDA (Food and Drug…